In contrast, the percentages of the CD3−CD16brCD56dim NK cells expressing inhibiting receptors NKG2A, KIR2DL1, and KIR3DL1 were not different between newly diagnosed CML patients and healthy controls (Figure 1A). This evidence concerns the gene KIR2DL1 and chronic myelogenous leukemia, BCR-ABL1 positive.